Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.

[1]  G. Filippatos,et al.  Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry , 2017, Diabetes Care.

[2]  Matthew J. Crowley,et al.  Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease , 2017, Annals of Internal Medicine.

[3]  D. Fitchett,et al.  Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes , 2017, European journal of heart failure.

[4]  L. Tarnow,et al.  Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial , 2017, European journal of heart failure.

[5]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[6]  K. Anstrom,et al.  Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.

[7]  M. Pencina,et al.  Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. , 2016, JAMA cardiology.

[8]  F. Porzsolt,et al.  Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.

[9]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[10]  Deepak L. Bhatt,et al.  Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". , 2015, Circulation.

[11]  M. Pencina,et al.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.

[12]  N. Chattipakorn,et al.  Dipeptidyl peptidase‐4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction , 2015, Experimental physiology.

[13]  W. Cushman,et al.  Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial , 2015, The Lancet.

[14]  Deepak L. Bhatt,et al.  Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. , 2015, Circulation.

[15]  Deepak L. Bhatt,et al.  Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial , 2014, Circulation.

[16]  M. Pfeffer,et al.  Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. , 2014, The lancet. Diabetes & endocrinology.

[17]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[18]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[19]  K. Connelly,et al.  DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. , 2013, Cardiovascular therapeutics.

[20]  Yan-Ling He.  Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin , 2012, Clinical Pharmacokinetics.

[21]  P. Liu,et al.  The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta‐analysis of randomized clinical trials , 2012, Journal of clinical pharmacy and therapeutics.

[22]  R. D. de Boer,et al.  Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure , 2011, Cardiovascular diabetology.

[23]  Adrian V. Hernández,et al.  Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[24]  Markolf Hanefeld,et al.  Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial , 2010, European heart journal.

[25]  Alfonso T. Perez,et al.  Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. , 2009, Congestive heart failure.

[26]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[27]  R. McKelvie,et al.  Diabetes, left ventricular systolic dysfunction, and chronic heart failure. , 2008, European heart journal.

[28]  J. McMurray,et al.  A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. , 2007, Journal of the American College of Cardiology.

[29]  J. Cohn,et al.  Ventricular remodeling in heart failure: a credible surrogate endpoint. , 2003, Journal of cardiac failure.

[30]  S. Yusuf,et al.  Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. , 2000, European heart journal.

[31]  J. Cohn,et al.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. , 2000, Journal of the American College of Cardiology.

[32]  B. Brundage,et al.  Left Ventricular Volume from Paired Biplane Two‐dimensional Echocardiography , 1979, Circulation.